Skip to search formSkip to main contentSkip to account menu

response to carboplatin

Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
New strategies for identification of therapeutic target of ovarian cancer
Ovarian cancer is the most lethal gynaecological cancer and one of the leading causes of cancer-related deaths among women… 
2019
2019
Major Response to Carboplatin in a Patient With Metastatic Triple-Negative Breast Cancer With Somatic Mutation of BRCA1 and Loss of RAD51B.
2018
2018
Characteristic response to carboplatin plus paclitaxel protein-bound after pembrolizumab.
2018
2018
A major response to carboplatin in a metastatic triple-negative breast cancer patient with somatic mutation of BRCA1 and RAD51B: When chemotherapy meets precision medicine.
2017
2017
Abstract 2421: The role of p53 mutational status and SOX9 suppression in chemotherapy response of ovarian cancer
Ovarian cancers are highly heterogeneous where platinum based chemotherapy which induces DNA crosslinking resulting in apoptosis… 
2016
2016
Abstract 4811: Global demethylation with decitabine increases DNA repair and sensitizes melanoma to carboplatin
Global genome repair (GGR) is critical for recognizing DNA damage by the chemotherapy agent carboplatin, and triggering apoptotic… 
2008
2008
c-Jun-NH2-terminal kinase potentiates apoptotic cell death in response to carboplatin in B lymphoma cells
PurposeExposure to carboplatin (CBDCA) has been demonstrated to result in apoptotic and/or necrotic cell death, but molecular… 
2007
2007
Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
1995
1995
Assessment of response to carboplatin in patients with hormone-refractory prostate cancer: a critical analysis of drug activity.
The clinical presentation of prostate-hormone refractory tumours in 90% of patients is characterised by sclerotic bone metastasis… 
1991
1991
Phase II study of carboplatin in advanced breast cancer: preliminary results.
The antitumor activity of carboplatin (400 mg/m2 intravenously every 4 weeks) in advanced breast cancer was evaluated in two… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)